Should we shift toward higher blood pressure targets in patients with chronic kidney disease?

Journal of Nephrology

Volumn 24, Issue 6, 2011, Pages 673-685

  Gentile, Giorgio ^a,b   Strippoli, Giovanni F M ^b,c,d,e  

^a UNIVERSITY OF PERUGIA   (Italy)

^b Diaverum Italy Medical Office   (Italy)

^c MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^d UNIVERSITY OF SYDNEY   (Australia)

^e Diaverum Medical Scientific Office   (Sweden)

Author keywords

Blood pressure targets; Chronic kidney disease; Diabetes mellitus; End stage kidney disease; Evidence based medicine; Hypertension

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; METOPROLOL; PLACEBO; RAMIPRIL; RAMIPRIL PLUS TELMISARTAN; TELMISARTAN; THIAZIDE DIURETIC AGENT; UNCLASSIFIED DRUG;

BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL PRACTICE; COMBINATION CHEMOTHERAPY; COST; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIALYSIS; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; GLOMERULOPATHY; GLOMERULUS FILTRATION RATE; GLYCEMIC CONTROL; HEART FAILURE; HUMAN; HYPERTENSION; INTERSTITIAL NEPHRITIS; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY POLYCYSTIC DISEASE; LOW DRUG DOSE; MACROALBUMINURIA; MEAN ARTERIAL PRESSURE; MICROALBUMINURIA; MONOTHERAPY; MORBIDITY; MORTALITY; NEPHROSCLEROSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PEDIATRICS; PRACTICE GUIDELINE; PROGNOSIS; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REPRODUCIBILITY; REVIEW; RISK FACTOR; RISK REDUCTION; SELF EXAMINATION; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; URINARY EXCRETION;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CHRONIC DISEASE; COMORBIDITY; DISEASE PROGRESSION; HUMANS; HYPERTENSION; KIDNEY DISEASES; PRACTICE GUIDELINES AS TOPIC;

EID: 80955132276     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: 10.5301/jn.5000052     Document Type: Review

References (95)

1. Kearney PM, Whelton M, Reynolds K, Whelton PK, He J. Worldwide prevalence of hypertension: a systematic review. J Hypertens. 2004;22(1):11-19.
2. Kotchen TA. Hypertension control: trends, approaches, and goals. Hypertension. 2007;49(1):19-20.
3. World Health Organization. Global health risks: mortality and burden of disease attributable to selected major risks. 2009. Available at: http://www.who.int/healthinfo/global_burden_disease/GlobalHealthRisks_report_full.pdf. Accessed Sept 29, 2011.
4. Bakris GL, Ritz E; World Kidney Day Steering Committee. The message for World Kidney Day 2009: hypertension and kidney disease-a marriage that should be prevented. J Hypertens. 2009;27(3):666-669
5. Chobanian AV, Bakris GL, Black HR, et al; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42(6):1206-1252.
6. Mancia G, De Backer G, Dominiczak A, et al; Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology. 2007 Guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25(6):1105-1187.
7. Williams B, Poulter NR, Brown MJ, et al; BHS guidelines working party, for the British Hypertension Society. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. BMJ. 2004;328(7440):634-640.
8. Hansson L, Zanchetti A, Carruthers SG, et al; HOT Study Group. Effects of intensive blood-pressure lowering and lowdose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet. 1998;351(9118):1755-1762.
9. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317(7160):703-713.
10. Estacio RO, Jeffers BW, Gifford N, Schrier RW. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care. 2000;23(Suppl 2):B54-B64.
11. Schrier RW, Estacio RO, Esler A, Mehler P. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int. 2002;61(3):1086-1097.
12. Thuraisingham RC, Yaqoob MM. Blood pressure guidelines in chronic kidney disease: a critical review. Nephron Clin Pract. 2009;113(4):c294-c300.
13. Coca SG, Krumholz HM, Garg AX, Parikh CR. Underrepresentation of renal disease in randomized controlled trials of cardiovascular disease. JAMA. 2006;296(11):1377-1384.
14. Strippoli GF, Craig MC, Schena FP, Craig JC. Role of blood pressure targets and specific antihypertensive agents used to prevent diabetic nephropathy and delay its progression. J Am Soc Nephrol. 2006;17(4)(Suppl 2):S153-S155.
15. Barsotti G, Del Vecchio L, Garibotto G, Gentile M, Oldrizzi L. [Conservative therapy guidelines for chronic renal failure] [article in Italian]. G Ital Nefrol. 2003;20(Suppl 24):S48-S60.
16. National Kidney Foundation. Kidney Disease Outcomes Quality Initiative (K/DOQI): clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis. 2004;43(5)(Suppl 1):S1-S290.
17. Harris D, Thomas M, Johnson D, Nicholls K, Gillin A; Caring for Australasians with Renal Impairment (CARI). The CARI guidelines: prevention of progression of kidney disease. Nephrology (Carlton). 2006;11(Suppl 1):S2-S197.
18. Del Vecchio L, Manno C, Ravani P, De Nicola L, Cianciaruso B. [Antihypertensive agents for the prevention of chronic kidney disease progression: guideline from the Italian Society of Nephrology] [article in Italian]. G Ital Nefrol. 2007;24(Suppl 37):64-82.
19. Chadban S, Howell M, Twigg S, et al. Prevention and management of chronic kidney disease in type 2 diabetes. Nephrology. 2010;15:S162-S194.
20. Kidney Disease: improving Global Outcomes (KDIGO). General Nephrology - Target Blood Pressure. Available at: http://www.kdigo.org/guidelines/compare/Table-General%20Nephrology-Target%20Blood%20Pressure.html. Accessed Sept 29, 2011.
21. Levin A, Hemmelgarn B, Culleton B, et al. Guidelines for the management of chronic kidney disease. CMAJ. 2008;179 (11):1154-1162.
22. British Renal Association. Cardiovascular disease in CKD. 2010. Available at: http://www.renal.org/Clinical/GuidelinesSection/CardiovascularDiseaseInCKD.aspx. Accessed Sept 29, 2011.
23. British Renal Association. Detection, monitoring and care of patients with CKD. 2011. Available at: http://www.renal.org/Clinical/GuidelinesSection/Detection-Monitoring-and-Careof-Patients-with-CKD.aspx. Accessed Sept 29, 2011.
24. Klag MJ, Whelton PK, Randall BL, et al. Blood pressure and end-stage renal disease in men. N Engl J Med. 1996;334(1):13-18.
25. Tozawa M, Iseki K, Iseki C, Kinjo K, Ikemiya Y, Takishita S. Blood pressure predicts risk of developing end-stage renal disease in men and women. Hypertension. 2003;41(6): 1341-1345.
26. Klahr S, Levey AS, Beck GJ, et al; Modification of Diet in Renal Disease Study Group. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. N Engl J Med. 1994;330(13):877-884.
27. Peterson JC, Adler S, Burkart JM, et al. Blood pressure control, proteinuria, and the progression of renal disease: the Modification of Diet in Renal Disease Study. Ann Intern Med. 1995;123(10):754-762.
28. Wright JT Jr, Bakris G, Greene T, et al; African American Study of Kidney Disease and Hypertension Study Group. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002;288(19):2421-2431.
29. Beck GJ, Berg RL, Coggins CH, et al; The Modification of Diet in Renal Disease Study Group. Design and statistical issues of the Modification of Diet in Renal Disease Trial. Control Clin Trials. 1991;12(5):566-586.
30. Lewis JB. Blood pressure control in chronic kidney disease: is less really more? J Am Soc Nephrol. 2010;21(7):1086-1092
31. Sarnak MJ, Greene T, Wang X, et al. The effect of a lower target blood pressure on the progression of kidney disease: long-term follow-up of the Modification of Diet in Renal Disease study. Ann Intern Med. 2005;142(5):342-351.
32. Taylor GJ, Wainwright P. Open label extension studies: research or marketing? BMJ. 2005;331(7516):572-574.
33. Day RO, Williams KM. Open-label extension studies: do they provide meaningful information on the safety of new drugs? Drug Saf. 2007;30(2):93-105.
34. Hemming K, Hutton JL, Maguire MJ, Marson AG. Open label extension studies and patient selection biases. J Eval Clin Pract. 2008;14(1):141-144.
35. Balamuthusamy S, Srinivasan L, Verma M, et al. Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: a metaanalysis. Am Heart J. 2008;155(5):791-805.
36. Kunz R, Friedrich C, Wolbers M, Mann JF. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med. 2008;148(1):30-48.
37. Sarafidis PA, Stafylas PC, Kanaki AI, Lasaridis AN. Effects of renin-angiotensin system blockers on renal outcomes and all-cause mortality in patients with diabetic nephropathy: an updated meta-analysis. Am J Hypertens. 2008;21(8):922-929.
38. Arguedas JA, Perez MI, Wright JM. Treatment blood pressure targets for hypertension. Cochrane Database Syst Rev. 2009;(3):CD004349.
39. Blacklock CL, Hirst JA, Taylor KS, Stevens RJ, Roberts NW, Farmer AJ. Evidence for a dose effect of renin-angiotensin system inhibition on progression of microalbuminuria in Type 2 diabetes: a meta-analysis. Diabet Med. 2011;28(10):1182-1187.
40. Upadhyay A, Earley A, Haynes SM, Uhlig K. Systematic review: blood pressure target in chronic kidney disease and proteinuria as an effect modifier. Ann Intern Med. 2011;154(8):541-548.
41. Maione A, Navaneethan SD, Graziano G, et al. Angiotensin- converting enzyme inhibitors, angiotensin receptor blockers and combined therapy in patients with microand macroalbuminuria and other cardiovascular risk factors: a systematic review of randomized controlled trials. Nephrol Dial Transplant. 2011;26(9):2827-2847.
42. Toto RD, Mitchell HC, Smith RD, Lee HC, McIntire D, Pettinger WA. "Strict" blood pressure control and progression of renal disease in hypertensive nephrosclerosis. Kidney Int. 1995;48(3):851-859.
43. Ruggenenti P, Perna A, Loriga G, et al; REIN-2 Study Group. Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomized controlled trial. Lancet. 2005;365(9463):939-946.
44. Appel LJ, Wright JT Jr, Greene T, et al; AASK Collaborative Research Group. Intensive blood-pressure control in hypertensive chronic kidney disease. N Engl J Med. 2010;363(10):918-929.
45. Gansevoort RT, Sluiter WJ, Hemmelder MH, de Zeeuw D, de Jong PE. Antiproteinuric effect of blood-pressure-lowering agents: a meta-analysis of comparative trials. Nephrol Dial Transplant. 1995;10(11):1963-1974.
46. Jafar TH, Schmid CH, Landa M, et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease: a meta-analysis of patient-level data. Ann Intern Med. 2001;135(2):73-87.
47. Maschio G, Alberti D, Janin G, et al; The Angiotensin- Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. Effect of the angiotensin-convertingenzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med. 1996;334(15):939-945.
48. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet. 1997;349(9069):1857-1863.
49. Kshirsagar AV, Joy MS, Hogan SL, Falk RJ, Colindres RE. Effect of ACE inhibitors in diabetic and nondiabetic chronic renal disease: a systematic overview of randomized placebo-controlled trials. Am J Kidney Dis. 2000;35(4):695-707.
50. Hou FF, Zhang X, Zhang GH, et al. Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Engl J Med. 2006;354(2):131-140.
51. Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med. 2001;134(8):629-636.
52. Asselbergs FW, Diercks GF, Hillege HL, et al; Prevention of Renal and Vascular Endstage Disease Intervention Trial (PREVEND IT) Investigators. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation. 2004;110(18):2809-2816.
53. Rahman M, Pressel S, Davis BR, et al. Renal outcomes in high-risk hypertensive patients treated with an angiotensinconverting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med. 2005;165(8):936-946.
54. Maki DD, Ma JZ, Louis TA, Kasiske BL. Long-term effects of antihypertensive agents on proteinuria and renal function. Arch Intern Med. 1995;155(10):1073-1080.
55. Jafar TH, Stark PC, Schmid CH, et al; AIPRD Study Group. Angiotensin-converting enzyme inhibition and progression of renal disease: proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. Kidney Int. 2001;60(3):1131-1140.
56. Ruggenenti P, Schieppati A, Remuzzi G. Progression, remission, regression of chronic renal diseases. Lancet. 2001;357(9268):1601-1608.
57. Khan NA, McAlister FA, Rabkin SW, et al; Canadian Hypertension Education Program. The 2006 Canadian Hypertension Education Program recommendations for the management of hypertension: Part II: therapy. Can J Cardiol. 2006;22(7):583-593.
58. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977-986.
59. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837-853.
60. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med. 2000;342(6):381-389.
61. Strippoli GF, Craig M, Deeks JJ, Schena FP, Craig JC. Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review. BMJ. 2004;329(7470):828.
62. Marre M, Lievre M, Chatellier G, Mann JF, Passa P, Ménard J; DIABHYCAR Study Investigators. Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study). BMJ. 2004;328(7438):495.
63. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet. 2000;355(9200):253-259.
64. Mann JF, Schmieder RE, McQueen M, et al; ONTARGET investigators. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet. 2008;372(9638):547-553.
65. Wühl E, Trivelli A, Picca S, et al; ESCAPE Trial Group. Strict blood-pressure control and progression of renal failure in children. N Engl J Med. 2009;361(17):1639-1650.
66. Heerspink HJ, Ninomiya T, Zoungas S, et al. Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials. Lancet. 2009;373(9668): 1009-1015.
67. National Kidney Foundation, K/DOQI Workgroup. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis. 2005;45(4)(Suppl 3):S1-S153.
68. Port FK, Hulbert-Shearon TE, Wolfe RA, et al. Predialysis blood pressure and mortality risk in a national sample of maintenance hemodialysis patients. Am J Kidney Dis. 1999;33(3):507-517.
69. Mazzuchi N, Carbonell E, Fernández-Cean J. Importance of blood pressure control in hemodialysis patient survival. Kidney Int. 2000;58(5):2147-2154.
70. Foley RN, Herzog CA, Collins AJ; United States Renal Data System. Blood pressure and long-term mortality in United States hemodialysis patients: USRDS Waves 3 and 4 Study. Kidney Int. 2002;62(5):1784-1790
71. Klassen PS, Lowrie EG, Reddan DN, et al. Association between pulse pressure and mortality in patients undergoing maintenance hemodialysis. JAMA. 2002;287(12):1548-1555.
72. Stidley CA, Hunt WC, Tentori F, et al; Medical Directors of Dialysis Clinic Inc. Changing relationship of blood pressure with mortality over time among hemodialysis patients. J Am Soc Nephrol. 2006;17(2):513-520
73. Myers OB, Adams C, Rohrscheib MR, et al. Age, race, diabetes, blood pressure, and mortality among hemodialysis patients. J Am Soc Nephrol. 2010;21(11):1970-1978.
74. Crews DC, Powe NR. Blood pressure and mortality among ESRD patients: all patients are not created equal. J Am Soc Nephrol. 2010;21(11):1816-1818.
75. Verdecchia P, Angeli F, Mazzotta G, Gentile G, Reboldi G. Home blood pressure measurements will not replace 24- hour ambulatory blood pressure monitoring. Hypertension. 2009;54(2):188-195.
76. Akpolat T. Home sphygmomanometers: what should a nephrologists know? J Nephrol. 2011;24(3):300-306.
77. Ingelfinger JR. Hypertension control in African-American patients with chronic kidney disease. N Engl J Med. 2010;363(10):974-976.
78. Jafar TH, Stark PC, Schmid CH, et al; AIPRD Study Group. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med. 2003;139(4):244-252.
79. Reboldi G, Gentile G, Angeli F, Ambrosio G, Mancia G, Verdecchia P. Effects of intensive blood pressure reduction on myocardial infarction and stroke in diabetes: a meta-analysis in 73,913 patients. J Hypertens. 2011;29(7):1253-1269.
80. National Heart Lung and Blood Institute. Systolic Blood Pressure Intervention Trial (SPRINT). 2011. Available at: http://clinicaltrials.gov/ct2/show/NCT01206062. Accessed Sept 29, 2011.
81. Reboldi G, Gentile G, Angeli F, Verdecchia P. Optimal therapy in hypertensive subjects with diabetes mellitus. Curr Atheroscler Rep. 2011;13(2):176-185.
82. Björck S, Mulec H, Johnsen SA, Nordén G, Aurell M. Renal protective effect of enalapril in diabetic nephropathy. BMJ. 1992;304(6823):339-343.
83. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD; The Collaborative Study Group. The effect of angiotensin-convertingenzyme inhibition on diabetic nephropathy. N Engl J Med. 1993;329(20):1456-1462.
84. Brenner BM, Cooper ME, de Zeeuw D, et al; RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345(12):861-869.
85. Lewis EJ, Hunsicker LG, Clarke WR, et al; Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345(12):851-860.
86. Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P; Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345(12):870-878.
87. Casas JP, Chua W, Loukogeorgakis S, et al. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and metaanalysis. Lancet. 2005;366(9502):2026-2033.
88. Rossing P, Parving HH, de Zeeuw D. Renoprotection by blocking the RAAS in diabetic nephropathy: fact or fiction? Nephrol Dial Transplant. 2006;21(9):2354-2357[discussion: 2357-2358].
89. Suissa S, Hutchinson T, Brophy JM, Kezouh A. ACE-inhibitor use and the long-term risk of renal failure in diabetes. Kidney Int. 2006;69(5):913-919.
90. Tobe SW, Clase CM, Gao P, et al; ONTARGET and TRANSCEND Investigators. Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies. Circulation. 2011;123(10):1098-1107.
91. Maione A, Nicolucci A, Craig JC, et al; LIRICO study group. Protocol of the Long-term Impact of RAS Inhibition on Cardiorenal Outcomes (LIRICO) randomized trial. J Nephrol. 2007;20(6):646-655.
92. Fried LF, Duckworth W, Zhang JH, et al; VA NEPHRON-D Investigators. Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D). Clin J Am Soc Nephrol. 2009;4(2):361-368.
93. Mario Negri Institute for Pharmacological Research. Preventing ESRD in Overt Nephropathy of Type 2 Diabetes (VALID). 2011. Available at: http://clinicaltrials.gov/ct2/show/study/NCT00494715. Accessed Sept 29, 2011.
94. Holtkamp FA, de Zeeuw D, de Graeff PA, et al. Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined RENAAL and IDNT trials. Eur Heart J. 2011;32(12):1493-1499.
95. De Nicola L, Borrelli S, Chiodini P, et al. Hypertension management in chronic kidney disease: translating guidelines into daily practice. J Nephrol. 2011 Feb 9. [Epub ahead of print].